Stoke Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.43) Per Share (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Leerink Partnrs issued their Q2 2024 earnings estimates for Stoke Therapeutics in a research report issued to clients and investors on Tuesday, April 9th. Leerink Partnrs analyst R. Li expects that the company will post earnings of ($0.43) per share for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2024 earnings at ($0.48) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($0.05) EPS.

A number of other analysts also recently weighed in on STOK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 26th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Thursday. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. Finally, Wedbush increased their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.63.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $12.77 on Friday. The business’s 50 day simple moving average is $8.01 and its 200 day simple moving average is $5.71. Stoke Therapeutics has a 1 year low of $3.35 and a 1 year high of $16.40. The company has a market capitalization of $591.25 million, a P/E ratio of -5.39 and a beta of 0.77.

Insider Activity

In related news, CFO Stephen J. Tulipano sold 4,116 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at approximately $126,550.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the sale, the chief financial officer now owns 20,746 shares in the company, valued at $126,550.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,741 shares of company stock worth $223,115. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Swiss National Bank raised its stake in shares of Stoke Therapeutics by 8.2% during the first quarter. Swiss National Bank now owns 30,500 shares of the company’s stock valued at $642,000 after acquiring an additional 2,300 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Stoke Therapeutics by 20.8% during the 1st quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company’s stock worth $412,000 after buying an additional 3,374 shares during the period. Bank of New York Mellon Corp grew its position in shares of Stoke Therapeutics by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after buying an additional 837 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Stoke Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 11,621 shares of the company’s stock valued at $245,000 after buying an additional 4,289 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Stoke Therapeutics by 7.6% in the first quarter. Rhumbline Advisers now owns 19,345 shares of the company’s stock valued at $407,000 after buying an additional 1,362 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.